FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947679917> ?p ?o ?g. }

• W2947679917 abstract "Pioglitazone, a synthetic peroxisome proliferator activated receptor (PPAR-γ) ligand, is known as an antidiabetic drug included in the thiazolidinediones (TZDs) class. It regulates the lipid and glucose cell metabolism and recently a role in the inhibition of numerous cancer cell processes has been described. In our work we investigate the anti-tumor effects of pioglitazone in in vitro models of non small cell lung cancer (NSCLC) and also, we generated ex-vivo three-dimensional (3D) cultures from human lung adenocarcinoma (ADK) as a model to test drug efficacy observed in vitro. The inhibitory effect of pioglitazone on cell proliferation, apoptosis and cell invasion in a panel of human NSCLC cell lines was evaluated by multiple assays. Pioglitazone reduced proliferative and invasive abilities with an IC50 ranging between 5 and 10 μM and induced apoptosis of NSCLC cells. mRNA microarray expression profiling showed a down regulation of MAPK, Myc and Ras genes after treatment with pioglitazone; altered gene expression was confirmed by protein analysis in a dose-related reduction of survivin and phosphorylated proteins levels of MAPK pathway. Interestingly mRNA microarray analysis showed also that pioglitazone affects TGFβ pathway, which is important in the epithelial-to-mesenchimal transition (EMT) process, by down-regulating TGFβR1 and SMAD3 mRNA expression. In addition, extracellular acidification rate (ECAR) and a proportional reduction of markers of altered glucose metabolism in treated cells demonstrated also cell bioenergetics modulation by pioglitazone. Data indicate that PPAR-γ agonists represent an attractive treatment tool and by suppression of cell growth (in vitro and ex vivo models) and of invasion via blockade of MAPK cascade and TGFβ/SMADs signaling, respectively, and its role in cancer bioenergetics and metabolism indicate that PPAR-γ agonists represent an attractive treatment tool for NSCLC." @default.
• W2947679917 created "2019-06-07" @default.
• W2947679917 creator A5009130863 @default.
• W2947679917 creator A5012201620 @default.
• W2947679917 creator A5016733143 @default.
• W2947679917 creator A5020655022 @default.
• W2947679917 creator A5025474253 @default.
• W2947679917 creator A5028284107 @default.
• W2947679917 creator A5032164411 @default.
• W2947679917 creator A5055583365 @default.
• W2947679917 creator A5056034569 @default.
• W2947679917 creator A5056367409 @default.
• W2947679917 creator A5059597630 @default.
• W2947679917 creator A5068882583 @default.
• W2947679917 creator A5069926525 @default.
• W2947679917 creator A5074105754 @default.
• W2947679917 date "2019-04-26" @default.
• W2947679917 modified "2023-10-13" @default.
• W2947679917 title "Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC" @default.
• W2947679917 cites W1504960949 @default.
• W2947679917 cites W1806952617 @default.
• W2947679917 cites W1906667240 @default.
• W2947679917 cites W1966969388 @default.
• W2947679917 cites W1971859682 @default.
• W2947679917 cites W1975796727 @default.
• W2947679917 cites W1991441696 @default.
• W2947679917 cites W2024309993 @default.
• W2947679917 cites W2031334428 @default.
• W2947679917 cites W2044774310 @default.
• W2947679917 cites W2072451938 @default.
• W2947679917 cites W2080411308 @default.
• W2947679917 cites W2117420591 @default.
• W2947679917 cites W2117938858 @default.
• W2947679917 cites W2119907371 @default.
• W2947679917 cites W2128211963 @default.
• W2947679917 cites W2164733896 @default.
• W2947679917 cites W2168086498 @default.
• W2947679917 cites W2170904194 @default.
• W2947679917 cites W2511313172 @default.
• W2947679917 cites W2564710034 @default.
• W2947679917 cites W2569597596 @default.
• W2947679917 cites W2610146492 @default.
• W2947679917 cites W2687483093 @default.
• W2947679917 cites W2763989125 @default.
• W2947679917 cites W2791362709 @default.
• W2947679917 cites W2792659208 @default.
• W2947679917 cites W2794080537 @default.
• W2947679917 cites W2935064944 @default.
• W2947679917 cites W4243903519 @default.
• W2947679917 cites W2018905080 @default.
• W2947679917 doi "https://doi.org/10.1186/s13046-019-1176-1" @default.
• W2947679917 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6485164" @default.
• W2947679917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31027492" @default.
• W2947679917 hasPublicationYear "2019" @default.
• W2947679917 type Work @default.
• W2947679917 sameAs 2947679917 @default.
• W2947679917 citedByCount "29" @default.
• W2947679917 countsByYear W29476799172019 @default.
• W2947679917 countsByYear W29476799172020 @default.
• W2947679917 countsByYear W29476799172021 @default.
• W2947679917 countsByYear W29476799172022 @default.
• W2947679917 countsByYear W29476799172023 @default.
• W2947679917 crossrefType "journal-article" @default.
• W2947679917 hasAuthorship W2947679917A5009130863 @default.
• W2947679917 hasAuthorship W2947679917A5012201620 @default.
• W2947679917 hasAuthorship W2947679917A5016733143 @default.
• W2947679917 hasAuthorship W2947679917A5020655022 @default.
• W2947679917 hasAuthorship W2947679917A5025474253 @default.
• W2947679917 hasAuthorship W2947679917A5028284107 @default.
• W2947679917 hasAuthorship W2947679917A5032164411 @default.
• W2947679917 hasAuthorship W2947679917A5055583365 @default.
• W2947679917 hasAuthorship W2947679917A5056034569 @default.
• W2947679917 hasAuthorship W2947679917A5056367409 @default.
• W2947679917 hasAuthorship W2947679917A5059597630 @default.
• W2947679917 hasAuthorship W2947679917A5068882583 @default.
• W2947679917 hasAuthorship W2947679917A5069926525 @default.
• W2947679917 hasAuthorship W2947679917A5074105754 @default.
• W2947679917 hasBestOaLocation W29476799171 @default.
• W2947679917 hasConcept C104317684 @default.
• W2947679917 hasConcept C134018914 @default.
• W2947679917 hasConcept C150194340 @default.
• W2947679917 hasConcept C150903083 @default.
• W2947679917 hasConcept C170493617 @default.
• W2947679917 hasConcept C185592680 @default.
• W2947679917 hasConcept C187345961 @default.
• W2947679917 hasConcept C190283241 @default.
• W2947679917 hasConcept C207001950 @default.
• W2947679917 hasConcept C26291073 @default.
• W2947679917 hasConcept C2775975398 @default.
• W2947679917 hasConcept C2777180221 @default.
• W2947679917 hasConcept C2778384471 @default.
• W2947679917 hasConcept C502942594 @default.
• W2947679917 hasConcept C55493867 @default.
• W2947679917 hasConcept C555293320 @default.
• W2947679917 hasConcept C62112901 @default.
• W2947679917 hasConcept C8415881 @default.
• W2947679917 hasConcept C86803240 @default.
• W2947679917 hasConcept C98274493 @default.
• W2947679917 hasConceptScore W2947679917C104317684 @default.
• W2947679917 hasConceptScore W2947679917C134018914 @default.

• next